Previous studies have supported this assumption, demonstrating that certain genetic variations, such as the G variation in PNPLA3 and the T variant in TM6SF2, are more prevalent among lean NAFLD patients [59], potentially impacting processes related to inflammation, oxidative stress and lipid metabolism [60–62]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.